Lipitor Trial To Study The Effect Of Torcetrpib/Atorvastatin To Atorvastatin Alone.

Pfizer

Status and phase: Completed; Phase 3

Conditions: Hyperlipidemia

Treatments: Drug: atorvastatin; Drug: torcetrapib/atorvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00137462

A5091019

Details and patient eligibility

About

The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

To look at various lipids in the blood of people with Fredrickson Type IIa and Type IIb mixed dyslipidemias

Full description

For additional information please call: 1-800-718-1021

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Statin eligible per NCEP ATP-III guidelines
• At least 18 years of age

Exclusion criteria

• Women who are pregnant or lactating, or planning to become pregnant
• Intolerance to statin therapy
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors
• Subjects with any other medical condition or laboratory abnormality which could affect subject safety, preclude evaluation of response, or render unlikely that the subject would complete the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind